Peer Review History
| Original SubmissionDecember 30, 2021 |
|---|
|
PONE-D-21-41019The direct and indirect costs of cardiovascular diseases in BrazilPLOS ONE Dear Dr. Moreira, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we suggest a major revision and invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by September 15, 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Pankaj Bahuguna, Ph.D. Guest Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. Additional Editor Comments:
[Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Reviewer Comments to authors General comments Thank you for the opportunity to review this manuscript. Overall, this is an important area of research and imperative to know the costs involved in cardiovascular diseases that are cause of high morbidity and mortality globally. The paper details on the costs involved but lacks clarity on costing methods used and standard terminologies for direct costs, unit costs involved and how authors arrived at them. Focus is more outlined for indirect costs, however both are important in cardiovascular diseases. For the better clarity and understanding of the readers, the language editing is required at multiple places in the current manuscript. Specific comments Abstract Line 26: It would be helpful to mention the study setting in the objective. Methods: Which of the costing approach was used in the study and what was the perspective of the costing exercise? Please add few details in the methodology. Results: Please rephrase the line 36 for better clarity. Line 40: Please add appropriate unit with age group defined. Introduction Line 48: Please clarify whether it is mortality rate or a different indicator where authors refer to lethality rate. It is unclear. Materials and methods Line 89 is unclear. What is implied by databases have time limits? Did it have any effect on the main analysis and final outcomes? It would be good to clarify here than referring elsewhere. Which costing approach and perspective was used for costing. Please provide details in the methodology section. Line 112-113: How was this ideal consumption identified? Please provide supporting reference and the reference standard taken. Line 120: The authors mention that food consumption was measured on non-consecutive days. Please provide details on choosing this rationale. Could this have introduced any bias and affected the analysis? Why were a sub sample chosen? It is unclear how many measurements and how many times in all at individual level were done to capture food consumption from the current manuscript. Line 126: It is unclear on whom and how the adherence test was done. Line 132: It would be good to mention the components of public expenses here for better understanding of the readers. Line 138-139: Were there any individuals who had both both CHD and stroke? How were these cases if there handled in the cost analysis? Results: Line 185-186: Is this the study finding or finding from literature review. It is unclear. If the latter then could be shifted to discussion. Discussion In general authors have extensively reviewed about various aspects but this section does not clearly outline key findings and their implications and is quite confusing to read. Few suggestions that could be helpful to authors to strengthen this very important aspect of the paper for better clarity and understanding to readers are: Introductory paragraph outlining what the study entailed, what was found, and why this is important in place of citing other paper on study design Summarising key findings of current study Importance of key findings in terms of what they tell us and implications of findings, in the context of what is already known in the literature and preferably in similar settings, and what is novel. Study limitations are mentioned. However, the authors mentioned in methods about limited time-limit of databases. Were there any limitations in for the data availability or health information management systems? Were any limitations present in relation to estimation of direct costs? Future direction/studies (optional) Reviewer #2: Introduction general comment: Can you specifically outline the policy rationale for undertaking this analysis looking at this specific relationship between nutrients, CVDs and costs It would be helpful for the reader to understand Brazilian sociodemographic characteristics specifically in terms of the population age characteristics to contextualize results better? Line 55: Could you please specify what the respective age scenarios are that you are referring to? Line 58: A brief overview of financing of Brazilian healthcare system along with these statements might be helpful Line 66: Please consider clearly rephrasing statements when you are referring to author names. Also, it would be helpful to know what these authors have concluded in their respective studies. Line 67: Grammatical error: ‘others’ should be replaced with ‘other’. Errors in structuring of sentences are quite common throughout the manuscript. It would help you to review these throughout the manuscript and to not use longer complex sentences. Line 69: ‘the’ needs to be replaced by ‘a’ Line 76: Could you give more evidence and references to back this claim? Line 79: What is the method generally used to know indirect costs? Line 81: Premature death cases are only due to CVD? How has this been established? Materials and Methods general comment: It would be helpful to outline the extent of indirect costs you are considering in the analysis with clear justification for doing so and providing a reason for excluding components of indirect costs that are not analysed in this analysis Line 89: I am not sure if the limits of databases have been adequately highlighted later in the manuscript or in limitations? Line 110: Could you please mention the currency exchange rate and its source as a reference? Line 116: How has individual food consumption been estimated from household food consumption dataset? Line 124: What is the multiple source method mentioned here? Line 132: Given that public expenses for CHD and stroke from available data sources are used, and that private expenses do account for healthcare costs in Brazil, how does this justify the projected costs? Line 148: Are costs only due to premature deaths accounted for? What about the costs due to morbidity/disability? Has this been accounted for in the analysis? Line 165: It is unclear to me why discounting has been used only for indirect costs given in the corresponding formula? Table 2: Any specific reason for as to why trans-fat consumption is relatively high in female population as compared to males? Discussion general comment: The relevance of these findings needs to be better contextualised to relevant policies in Brazil. Please identify and discuss specific aspects of policies that can be addressed given the findings of this study. Line 309: 110,000 and 70,000 cases of what? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-21-41019R1 The direct and indirect costs of cardiovascular diseases in Brazil PLOS ONE Dear Dr. Moreira, Thank you for submitting the revised manuscript to PLOS ONE. The revised manuscript has improved significantly but after careful consideration, we feel there is still scope of further improvement. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by 15th November 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Pankaj Bahuguna, Ph.D. Guest Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: (No Response) Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Thank you for revising the manuscript and improving clarity for better understanding of the readers. However, the paper still needs language editing at few places and use of shorter sentences. Abstract Line 24-25: It could be useful to know whether the cost mentioned here was overall cost/health system cost/societal cost and specifically for treatment? Line 27-28: Were these direct medical costs only? Please specify if so. Line 29-30 can be rephrased to shorter sentences for better clarity. Results: Line 33: Higher burdens of what attributable to? Conclusion Line 39: “Studies of this nature….” Is very broad scope and could be rephrased to narrower scope for clarity. Also authors may use shorter sentences in conclusion and should restrict to findings from the study than generic statements. Introduction Line 44: This line may be rephrased to “Cardiovascular diseases (CVD) are one of the key challenges in health globally, since……………” Line 78: Please cite supporting references besides “few studies…….” Or may rephrase. Line 85-86 looks repetitive in lines 94-96 and may be better placed there. Lines 87-89 seems better suited to methodology section. Line 99 could be rephrased to “Several databases were referred to collect and analyse CVD cost related information between 2017 and 2019 for Brazil.” Line 114: There seems to be incomplete word in here. Whether its three sources or three databases, it is currently unclear to understand “three bases”. Discussion Line 293: The sentence could be rephased to “Findings from or study showed………….” Reviewer #2: Thank you for considering suggestions and revising the manuscript. The manuscript content is structured better and reads more logically now. The authors have addressed grammatical mistakes to a large extent. Policy relevance of this work is highlighted better than the previous version. Following are some of my suggestions/clarifications for the revised manuscript (Line numbers refer to the latest unmarked version): Consider further grammatical checks: For example, replace burdens with burden (multiple places, replace servings with serving – Line 158, typos on Line 214-215, Replace manuscript with ‘study’ – Line 293, typo error on Line 295, typo on Line 375, consider replacing ‘inadequate diet’ with maybe unhealthy diet if you thing that is more reflective on Line 305. You may consider further similar grammatical checks in the manuscript. The revised introduction section makes a better read. However, on line 87, you go on to directly explain methods of indirect cost analysis. I would suggest you consider moving this to the methods section. The introduction section could give a brief overview of what all analysis (PAF, direct cost, indirect costs) is being aimed. Similarly, I found it difficult to establish relevance of Line 69-70 in context to the previous statement. What do you mean by recurrent costs here? My understanding is recurrent costs would be those attributed to hospitalisations and consultations (22% of costs) For lines 137 to 143 – Can you clarify if adjusted relative risk values should be used for PAF calculation instead of relative risk? For lines 198 to 201 – Can you give any rationale/reasoning/references for choosing the six explanatory variables that have been chosen? Based on your results, specifically tables 1 and 2, can anything be commented/discussed on relationship between PAF and direct costs that you have observed? In discussion, can you compare findings of high costs and mortality for males as compared to females with any existing evidence from Brazil to possibly validate your result? For Table 4 from Line 290 onwards – I do not understand the unit used for your findings. The reported YLL is for what unit of observation? Is it for the entire cohort, per number of cases or what exactly? In discussion section, can you compare your indirect cost findings to any other relevant literature? ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
The direct and indirect costs of cardiovascular diseases in Brazil PONE-D-21-41019R2 Dear Dr Moreira, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Pankaj Bahuguna, Ph.D. Guest Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-41019R2 The direct and indirect costs of cardiovascular diseases in Brazil Dear Dr. Moreira: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr Pankaj Bahuguna Guest Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .